Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-08-25
2010-02-09
Peng, Bo (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S252300
Reexamination Certificate
active
07659382
ABSTRACT:
The invention provides novel TRIM polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length TRIM proteins, the invention further provides isolated TRIM fusion proteins, antigenic peptides and anti-TRIM antibodies. The invention also provides TRIM nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an TRIM gene has been introduced or disrupted. The present invention also provides methods and compositions for the diagnosis and treatment of viral infection and/or replication, e.g., HIV infection. The invention further provides methods for identifying a compound capable of treating or preventing viral infection and/or replication, e.g., HIV infection and AIDS. In addition, the invention provides a method for treating a subject having a viral infection and/or replication, e.g., HIV infection using the modulators of the invention.
REFERENCES:
Jarvis DL, et al. “Immediate-early baculovirus vectors for foreign gene expression in transformed or infected insect cells.” Protein Expr Purif. Sep. 1996;8(2):191-203.
Sawyer et al. “Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain.” (PNAS, 102(8):2832-2837).
Stremlau M, Perron M, Welikala S, Sodroski J. “Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.” J Virol. Mar. 2005;79(5):3139-45.
Nakayama, et al. “A Specific Region of 37 Amino Acid Residues in the SPRY (B30.2) Domain of African Green Monkey TRIM5 Determines Species-Specific Restriction of Simian Immunodeficiency Virus SIVmac Infection” Virology 2005, 79(14):8870-7.
Sawyer et al. “Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain.” PNAS, 102(8):2832-2837, 2005.
Marcello, A. et al., “Recruitment of human cyclin T1 to nuclear bodies through direct interaction with the PML protein,” EMBO J. 22(9):2156-2166 (2003).
Mariani, R. et al., “Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif,” Cell 114:21-31 (2003).
Munk, C, et al., “A dominant block to HIV-1 replication at reverse transcription in simian cells,” Proc. Natl. Acad. Sci. USA 99:13843-13848 (2002).
NCBI RefSeq NM—033034 (gi:14719417).
NCBI RefSeq NM—033092 (gi:15011943).
Niikura, T., et al., “A tripartite motif protein TRIM11 binds and destabilizes Humanin, a neuroprotective peptide against Alzheimer's disease-relevant insults,” Eur. J. Neurosci. 17:1150-1158 (2003).
Nisole, S., et al., “A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1,” Proc. Natl. Acad. Sci. USA 101(36):13324-13328 (2004).
Owens, C. M., et al., “Human and Simian Immunodeficiency Virus Capsid Proteins Are Major Viral Determinants of Early, Postentry Replication Blocks in Simian Cells,” J. Virol. 77:726-731 (2003).
Owens, C. M., et al., “Binding and Susceptibility to Postentry Restriction Factors in Monkey Cells Are Specified by Distinct Regions of the Human Immunodeficiency Virus Type 1 Capsid,” J. Virol. 78:5423-5437 (2004).
Pieribone, D., “The HIV Life Cycle,” AEGiS-ACRIA: ACRIA News—The HIV Life Cycle—Winter 2002/2003 ww.aegis.com/pubs/cria/2003/CR030111.html (2003).
Reddy, B.A., et al., “A novel zinc finger coiled-coil domain in a family of nuclear proteins,” Trends Biochem. Sci., 17:344-345 (1992).
Reymond, A., et al., “The tripartite motif family identifies cell compartments,” EMBO J. 20:2140-2151 (2001).
Rho, H. M., et al., “Characterization of the Reverse Transcriptase from a New Retrovirus (HTLV) Produced by a Human Cutaneous T-Cell Lymphoma Cell Line,” Virology 112:355-360 (1981).
Rhodes, D.A. et al., “The 52 000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-γ inducible tripartite motif protein associated with membrane proximal structures,” Immunol. 106:246-256 (2002).
Sayah, D. M., et al., “Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1,” Nature 430(6999):569-573 (2004).
Schwartz, O. et al., “Antiviral Activity of the Proteasome on Incoming Human Immunodeficiency Virus Type 1,” J. Virol. 72(5):3845-3850 (1998).
Seto, M. H., et al., “Protein Fold Analysis of the B30.2-Like Domain,” Proteins: Structure, Function, and Genetics 35:235-249 (1999).
Shibata, R., et al., “Early replication block of human immunodeficiency virus type 1 in monkey cells,” J. Gen. Virol. 76:2723-2730 (1995).
Stremlau, M., et al., “The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys,” Nature 427:848-853 (2004).
Toniato, E. et al., “TRIM8/GERP Ring Finger Protein Interacts with SOCS-1,” J. Biol. Chem. 277(40):37315-37322 (2002).
Towers, G., et al., “A conserved mechanism of retrovirus restriction in mammals,” Proc. Natl. Acad. Sci. USA 97:12295-12299 (2000).
Birtri et al., “TRIM9 is specifically expressed in the embryonic and adult nervous system,” Mech. Dev., 113(2):159-162 (2002).
International Search Report dated Jun. 4, 2008 from PCT/US05/05458 (DFS-058.25).
Arts, E. J., and M. A. Wainberg, “Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription,” Adv. Virus Res. 46:97-163 (1996).
Barre-Sinoussi, F., et al., “Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS),” Science 220:868-871 (1983).
Besnier, C, et al., “Restriction of lentivirus in monkeys,” Proc. Natl. Acad. Sci. USA 99:11920-11925 (2002).
Bieniasz P. D., “Restriction factors: a defense against retroviral infection,” Trends Microbiol. 11:286-291 (2003).
Bonilla, W.V. et al., “Effects of Promyelocytic Leukemia Protein on Virus-Host Balance,” J. Virol. 76(8):3810-3818 (2002).
Borden, K.L., “Ring fingers and B-boxes: zinc-binding protein-protein interaction domains,” Biochem. Cell Biol., 76:351-358 (1998).
Butler, S., et al., “A quantitative assay for HIV DNA integration in vivo,” Nat. Med. 7, 631-634 (2001).
Chee, A.V. et al., “Promyelocytic Leukemia Protein Mediates Interferon-Based Anti-Herpes Simplex Virus 1 Effects,” J. Virol. 77(12):7101-7105 (2003).
Clavel, F., “Editorial Review HIV-2, the West African AIDS Virus,” AIDS 1:135-140 (1987).
Cowan, S., et al., “Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism,” Proc. Natl. Acad. Sci. USA 99:11914-11919 (2002).
Daniel, M. D., et al., “Isolation of T-cell tropic HTLV-III-like retrovirus from Macaques,” Science 228:1201-1204 (1985).
Desrosiers, R. C., “The simian immunodeficiency viruses,” Ann. Rev. Immunol. 8: 557-578 (1990).
Dorfman, T. & Göttlinger, H.G., “The Human Immunodeficiency Virus Type I Capsid p2 Domain Confers Sensitivity to the Cyclophilin-Binding Drug SDZ NIM 811,” J. Virol. 70, 5751-5757 (1996).
Fassati, A. and Goff, S.P., “Characterization of Intracellular Reverse Transcription Complexes of Human Immunodeficiency Virus Type I,” J. Virol. 75, 3626-3635 (2001).
Fauci, A., et al., “NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations,” Ann. Int. Med. 100:92-106 (1984).
Feng, Y., et al., “HIV-1 entry cofactor: functional cDNA clonong of a seven-transmembrane, G protein-coupled receptor,” Science 272, 872-877 (1996).
Forshey et al., “Formation of a Human Im
Owens Christopher M.
Sodroski Joseph
Stremlau Matthew
Dana-Farber Cancer Institute Inc.
Foley & Hoag LLP
Peng Bo
LandOfFree
Methods and compositions for the treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4234379